Related Experiment Videos
Recent developments in oral hypoglycemic agents
1Central Pharmaceutical Research Institute, JT Inc., 1-1 Muracaki-cho, Takatsuki, Osaka, 569-1125, Japan.
Abstract:
Recent large-scale studies in patients with type 2 diabetes have suggested that improved glycemic control will reduce the incidence and severity of chronic complications. However, it is difficult to maintain the blood glucose levels of diabetic patients within a narrow range. Since insulin resistance and impaired insulin secretion cause hyperglycemia in type 2 diabetes, both improvement of insulin resistance and compensation for defective insulin secretion are necessary. Recently, the first insulin sensitizer was released, and a short-acting insulinotropic agent, which should be more convenient for strict glycemic control than sulfonylureas, has also been launched. This review focuses on these two new classes of hypoglycemic agents.
Insights
New treatments for type 2 diabetes focus on improving insulin sensitivity and secretion. These agents offer better glycemic control to reduce chronic complications in diabetic patients.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes management is challenging due to difficulties in maintaining optimal blood glucose levels.
- Hyperglycemia in type 2 diabetes results from insulin resistance and impaired insulin secretion.
- Chronic complications of diabetes underscore the need for improved glycemic control.
Purpose of the Study:
- To review two novel classes of hypoglycemic agents for type 2 diabetes.
- To highlight agents that address both insulin resistance and defective insulin secretion.
Main Methods:
- Review of recent literature on new hypoglycemic agents.
- Focus on insulin sensitizers and short-acting insulinotropic agents.
Main Results:
- The introduction of insulin sensitizers addresses insulin resistance.
- New short-acting insulinotropic agents offer improved convenience for glycemic control compared to sulfonylureas.
Conclusions:
- Novel hypoglycemic agents provide new strategies for managing type 2 diabetes.
- These agents aim to improve glycemic control and reduce long-term complications.